| 16330-3 |
Aldosterone^7th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16330-3 |
|
|
|
|
Observation |
|
|
|
0 |
Aldost sp7 p chal SerPl-mCnc |
|
|
|
Y |
|
^7th spec pst XXX chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp7; sp7 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 16331-1 |
Aldosterone^8th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16331-1 |
|
|
|
|
Observation |
|
|
|
0 |
Aldost sp8 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp8; sp8 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 16332-9 |
Aldosterone^9th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16332-9 |
|
|
|
|
Observation |
|
|
|
0 |
Aldost sp9 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp9; sp9 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 16333-7 |
Aldrin |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Aldrin [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16333-7 |
|
|
|
|
Both |
|
|
|
0 |
Aldrin Bld-mCnc |
|
|
|
Y |
|
Aldocit; Aldrex; Aldrite; Aldrosol; Blood; Compound 118; Dimethanonaphthalene; Drinox; DRUG/TOXICOLOGY; Drugs; HHDM; HHDN; HHPN; Kortofin; Level; Mass concentration; Octalene; OMS-194; Point in time; QNT; Quan; Quant; Quantitative; Random; Seedrin; Tatuzinho; Tipula; WB; Whole blood |
2.68 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16334-5 |
Alfentanil |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Alfentanil [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16334-5 |
|
|
|
|
Both |
|
|
|
0 |
Alfentanil Ur-mCnc |
|
|
|
Y |
|
Alfenta; DRUG/TOXICOLOGY; Drugs; Fanaxal; Level; Limefen; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Rapifen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16335-2 |
Hydrocarbons.aliphatic |
Prid |
Bld |
Pt |
Nom |
|
|
ACTIVE |
Hydrocarbons Aliphatic [Identifier] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16335-2 |
|
|
|
|
Both |
|
|
|
0 |
Aliph HC Bld |
|
|
|
|
|
Aliph HC; Blood; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Point in time; Random; WB; Whole blood |
2.17 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16336-0 |
Alkaline phosphatase.placental |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Alkaline phosphatase.placental [Enzymatic activity/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16336-0 |
|
|
|
|
|
|
|
|
0 |
Deprecated ALP Plac SerPl-cCnc |
|
|
|
|
|
Alk; Alk phos; Alkaline phos; Alkaline phosphatase.total; ALKP; ALP; ALP Plac; AP; Catalytic Concentration; Chemistry; Phos; Phosphtase; Pl; Placent; Placenta; Placntl; PLAP; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16337-8 |
Alkaline phosphatase |
CCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Alkaline phosphatase [Enzymatic activity/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
16337-8 |
|
|
|
|
Both |
|
|
|
0 |
ALP Ur-cCnc |
|
|
|
Y |
|
Alk; Alk phos; Alkaline phos; Alkaline phosphatase.total; ALKP; ALP; AP; Catalytic Concentration; Chemistry; Hepatology; Liver; MSK; Musculoskeletal; Ortho; Orthopedics; Phos; Phosphtase; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.68 |
1.0l |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
| 16338-6 |
Alpha aminoadipate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Alpha aminoadipate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16338-6 |
|
|
|
|
Observation |
|
|
|
0 |
AAA Ur Ql |
|
|
|
|
|
2-aminoadipate; 2-aminoadipic acid; AAA; AAD; Alfa; Alpha aminoadipic acid; Aminoadipic acid; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16339-4 |
Alpha aminoisobutyrate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Alpha aminoisobutyrate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16339-4 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB Ur Ql |
|
|
|
|
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AIB; Alfa; alpha aminoisobutyric acid; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1634-5 |
Somatotropin^52H post 250 ug L-Dopa TID 2day PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --52 hours post 250 ug L-dopa TID 2day PO |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
1634-5 |
|
|
|
|
Observation |
|
|
|
0 |
GH 52h p 250 ug L-D TID 2D PO SerPl-mCnc |
|
|
|
Y |
|
52h p 250 ug L-D TID 2D PO; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Left; Level; Levo; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; three times a day |
2.4 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16340-2 |
Alpha aminoisobutyrate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Alpha aminoisobutyrate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16340-2 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB Ur-mCnc |
|
|
|
Y |
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AIB; Alfa; alpha aminoisobutyric acid; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16341-0 |
Alpha aminoisobutyrate |
PrThr |
Plas |
Pt |
Ord |
|
|
ACTIVE |
Alpha aminoisobutyrate [Presence] in Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16341-0 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB Plas Ql |
|
|
|
|
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AIB; Alfa; alpha aminoisobutyric acid; Chemistry; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16342-8 |
Alpha aminoisobutyrate |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Alpha aminoisobutyrate [Mass/volume] in Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16342-8 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB Plas-mCnc |
|
|
|
Y |
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AIB; Alfa; alpha aminoisobutyric acid; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16343-6 |
Alpha aminoisobutyrate |
MCnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Alpha aminoisobutyrate [Mass/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16343-6 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB CSF-mCnc |
|
|
|
Y |
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AIB; Alfa; alpha aminoisobutyric acid; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16344-4 |
Alpha aminoisobutyrate |
MCnc |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Alpha aminoisobutyrate [Mass/volume] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16344-4 |
|
|
|
|
Observation |
|
|
|
0 |
A-AIB Amn-mCnc |
|
|
|
Y |
|
2-aminoisobutyrate; 2-aminoisobutyric acid; 2-methylalanine; A-AIB; AF; AIB; Alfa; alpha aminoisobutyric acid; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 16345-1 |
Alpha aminobutyrate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Alpha aminobutyrate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16345-1 |
|
|
|
|
Observation |
|
|
|
0 |
A-Aminobutyr Ur Ql |
|
|
|
|
|
2-aminobutanoic acid; 2-aminobutyrate; 2-aminobutyric acid; A-Aminobutyr; AANB; A-ANB; Alfa; Alpha aminobutyric acid; Alpha amino-n-butyrate; Alpha amino-n-butyric acid; Aminobutric; Aminobutyric; Amino-n-butyrate; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16346-9 |
Alpha chlordane |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Alpha chlordane [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16346-9 |
|
|
|
|
Both |
|
|
|
0 |
A-Chlordane Ur-mCnc |
|
|
|
Y |
|
A-Chlordane; Alfa; Belt; Chlor Kil; Chlordan; Chlortox; Clordano; Corodane; DRUG/TOXICOLOGY; Drugs; Gold Crest C-100; Kilex Lindane; Kypchlor; Level; Mass concentration; Niran; Octachlor; Octa-Klor; Point in time; QNT; Quan; Quant; Quantitative; Random; Synklor; Topiclor 20; Toxichlor; UA; UR; Urn; Velsicol 1068 |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16347-7 |
Alpha chlordane |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Alpha chlordane [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16347-7 |
|
|
|
|
Both |
|
|
|
0 |
A-Chlordane Bld-mCnc |
|
|
|
Y |
|
A-Chlordane; Alfa; Belt; Blood; Chlor Kil; Chlordan; Chlortox; Clordano; Corodane; DRUG/TOXICOLOGY; Drugs; Gold Crest C-100; Kilex Lindane; Kypchlor; Level; Mass concentration; Niran; Octachlor; Octa-Klor; Point in time; QNT; Quan; Quant; Quantitative; Random; Synklor; Topiclor 20; Toxichlor; Velsicol 1068; WB; Whole blood |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16348-5 |
Alpha hydroxyalprazolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16348-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz Ur Cfm-mCnc |
|
|
|
Y |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Level; Mass concentration; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16349-3 |
Aluminum |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Aluminum [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
16349-3 |
|
|
|
|
Both |
|
|
|
0 |
Aluminum Fld-mCnc |
|
|
|
Y |
|
AL; Aluminium; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 1635-2 |
Somatotropin^pre 1 g/kg glucose PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --pre 1 g/kg glucose PO |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
1635-2 |
|
|
|
|
Observation |
|
|
|
0 |
GH pre 1 g/kg Glc PO SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; Growth hormone; GTT; HGH; Human growth hormone; i; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre 1 g/kg Glc PO; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16350-1 |
Amantadine |
Titr |
Isolate+Ser |
Pt |
SemiQn |
SBT |
|
ACTIVE |
Amantadine [Susceptibility] by Serum bactericidal titer |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
ABXBACT |
|
16350-1 |
|
SBT |
|
|
Observation |
|
|
|
0 |
Amantadine Titr SBT |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; Atarin; Contenton; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Influenol; Islt; Isol; Mantadan; Paramantin; Point in time; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Symmetrel; Titer; Titered; Titre; Ttr; Virofal |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 16351-9 |
aMILoride |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
aMILoride [Units/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16351-9 |
|
|
|
|
Both |
|
|
|
0 |
aMILoride SerPl-aCnc |
|
|
|
Y |
|
Amikal; Amilospare; Amipramizide; Arbitrary concentration; DRUG/TOXICOLOGY; Drugs; Kaluril; Midamor; Modamide; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16352-7 |
aMILoride |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
aMILoride [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16352-7 |
|
|
|
|
Both |
|
|
|
0 |
aMILoride Ur-aCnc |
|
|
|
Y |
|
Amikal; Amilospare; Amipramizide; Arbitrary concentration; DRUG/TOXICOLOGY; Drugs; Kaluril; Midamor; Modamide; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
